Investigating how DNA repeat silencing affects prostate cancer treatment with ATR inhibitors
Official title: Effect of DNA repeat silencing on efficacy of ATRi in prostate cancer treatment
Funded at University of Pennsylvania · NIH-11059841 · Data updated 2026-11-12
This study is looking at how certain changes in the DNA of advanced prostate cancer cells can make them more responsive to a new type of treatment called ATR inhibitors, with the goal of finding better ways to help patients with hard-to-treat prostate cancer.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of Pennsylvania NIH-funded |
| Lab location | 1 site (Philadelphia, United States) |
| Project start | April 3, 2023 |
| Project end | March 31, 2028 |
| Funding year | 2025 |
| Award (this year) | $347,378 |
| NIH project number | 5R01CA266645-03 |
| Project ID | NIH-11059841 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for participation are individuals diagnosed with advanced prostate cancer, especially those with castration-resistant forms of the disease.
✕Less likely to help
Patients with early-stage prostate cancer or those who do not have advanced disease may not benefit from this research.
What this research studies
This research explores the role of DNA repeat silencing in enhancing the effectiveness of ATR inhibitors (ATRi) for treating advanced prostate cancer, particularly castration-resistant prostate cancer (CRPC). The study aims to understand how certain genetic changes in cancer cells can increase their sensitivity to ATRi by promoting the transcription of specific DNA sequences. By examining the impact of these alterations, the research seeks to identify potential strategies to improve treatment outcomes for patients with advanced prostate cancer. Patients may be involved in trials that assess the effectiveness of these new treatment approaches.
Why it matters
Potential benefit: If successful, this research could lead to more effective treatment options for patients with advanced prostate cancer.
How similar studies have gone: Previous research has shown promising results with ATR inhibitors in cancer treatment, indicating potential for success with this novel approach.
Where this research is happening
-
University of Pennsylvania
Philadelphia, United States Active
Researchers
- Principal investigator: Brown, Eric J — University of Pennsylvania
- Study coordinator: Brown, Eric J
Related research
Other NIH-funded projects on the same topics.
-
Cardiovascular risk planning and reduction for men with prostate cancer
A program to better predict and reduce heart disease risk in men treated for prostate cancer, especially older patients.
-
Effects of ADT on motivation and emotion in prostate cancer patients
This project looks at how androgen deprivation therapy may affect motivation and mood over time in men with prostate cancer.
-
Causal Protein Markers to Understand and Predict Prostate Cancer Risk in Africans and Europeans
A cancer research project looking at proteins linked to prostate cancer to better understand why it happens and how risk differs between African and European populations.
-
Ethical multimodal AI platform to improve prostate cancer detection with ultrasound
A patient-friendly AI system uses ultrasound and MRI information to help doctors better find prostate cancer, aiming to improve accuracy and access.
-
Characterizing epigenetic targets in prostate cancer to help AR-driven cancer
A research project at MD Anderson aims to understand how epigenetic factors shape androgen receptor signaling in prostate cancer to find new ways to treat resistant forms of the disease.
-
AR and RNA-binding in prostate cancer resistance
A cancer research grant exploring how the androgen receptor’s interaction with RNA may drive treatment resistance in prostate cancer, with potential to guide new therapies.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.